Advanced HIV Disease During the First Six Months on Antiretroviral Therapy in Zambia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

11800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-04-22

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In Zambia, an estimated 20% of HIV-positive clients continue to present for first-time antiretroviral therapy (ART) initiation or re-initiation with advanced HIV disease (AHD). The Zambia Ministry of Health (MOH) and other key stakeholders lack information about the characteristics and behaviors of AHD clients, including how they are defined and diagnosed (e.g. low CD4 count v. clinical condition), their demographic and socioeconomic profiles, their HIV care histories, what services they receive, and their short-term outcomes (achieve viral suppression, remain AHD, disengage from care, die) and the timing of these outcomes.

The Retain6 project aims to improve HIV treatment outcomes during clients' first six months on ART, when disengagement from care and mortality are highest. This protocol, called Advanced HIV disease during the first six months on antiretroviral therapy in Zambia (AHD Zambia), describes an observational study that will describe the experiences of clients who are diagnosed with AHD upon ART initiation (or re-initiation) in Zambia. Data collected will include clinical and socioeconomic characteristics, clinical and non-clinical needs, services delivered and received, and clients' and providers' concerns and preferences. The study's overall goal is to provide information to the Zambia MOH, treatment program partners, providers, and other stakeholders to better understand who is presenting with AHD in Zambia, how they are currently managed, and their treatment outcomes after starting ART. This information will be useful in determining interventions and guideline changes that might improve short- and long-term outcomes for AHD patients.

The study, which will be conducted in collaboration with the Zambia MOH, will include retrospective file reviews, prospective quantitative surveys with outpatient and inpatient clients, qualitative focus group discussions (FGDs) and interviews with clients, and provider surveys and interviews.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in Zambia

NCT05454852

HIV

ACTIVE_NOT_RECRUITING

Examining HIV Treatment Adherence During Early Disease

NCT02419066

Medication Adherence HIV

COMPLETED

Differentiated Care for Improved Health Systems Efficiency and Health Outcomes in Zambia

NCT02776254

HIV

COMPLETED NA

Gathering Records to Evaluate Antiretroviral Treatment-Zambia (GREAT )

NCT04158882

HIV

RECRUITING

A Comparison of Different Community Models of ART Delivery Amongst Stable HIV+ Patients in Two Urban Settings in Zambia

NCT03025165

HIV Infections

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced HIV Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1. Prospective cohort

Cohort 1 is a prospective cohort of adults screened for AHD during the approximately three-month data collection period of the AHD Zambia study. Clients will be enrolled into the study if they 1) are not on ART or have been on ART for up to one month, and 2) are screened for AHD on the day of study enrollment or, if missed on the day they are screened for AHD, will be enrolled at the next clinic visit within one month of AHD screening. Record review for up to 12 months before and 12 months after study enrollment. Baseline survey and qualitative follow up.

No interventions assigned to this group

2. Hybrid cohort

Cohort 2 is a hybrid cohort of all adult HIV clients recorded in study sites' AHD screening registers, improvised registers, and/or clinic records as having been screened for AHD at or before ART initiation in the 12 months preceding the start of Cohort 1 data collection. Electronic and paper medical record data will be collected for all of Cohort 2 for the 12 months before and 12 months after the AHD screening date. A subset of Cohort 2 respondents-those who return to the study sites for a clinic visit during the data collection period-will be invited to consent and participate in a quantitative survey and in follow-up qualitative interviews, similar to Cohort 1 enrollees.

No interventions assigned to this group

3. Inpatient cohort

Cohort 3 includes adult HIV clients admitted in a study health facility for AHD management. Under the Zambia Ministry of Health's "hub and spoke model" for AHD management, AHD patients requiring hospitalization are admitted to hub facilities. Of the 24 study facilities in AHD-Zambia, 8 are hubs that admit AHD patients. The remaining 16 study sites refer AHD clients requiring admission to the nearest hospital. We will enroll Cohort 3 only at the 8 sites that offer inpatient admission for AHD.

No interventions assigned to this group

4. Provider cohort

At each study site, we will ask the facility manager to refer us to up to 5 staff who provide care for AHD clients and represent different cadres. This may include doctors and clinical officers, nurses, counselors, and pharmacists, though we anticipate the majority of respondents to be doctors, nurses and clinical officers, who provide most HIV care in Zambia. Each cohort participant will be administered a one-time survey regarding AHD care at the facility.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥18 years old
* Presenting at a study site clinic for HIV diagnosis or care
* Not currently on ART (or on ART for up to 1 month if enrolled at next visit after AHD screening)
* Screened for AHD by clinic, prior to or within 1 month of ART initiation
* Written informed consent to participate

Exclusion

* Pregnant and/or presenting for antenatal care
* Too ill at the time of AHD screening and at the next clinic visit to participate in the study
* Unable to communicate in any of the languages into which the questionnaire has been translated or that is known to the research assistant

Cohort 2

Inclusion

* ≥18 years old
* Living with HIV and screened for AHD at a study site within 12 months of the start of study prospective data collection at that site
* Initiated/re-initiated ART within the past 6 months
* Returns to the study site for a clinic visit during the study enrollment period
* Written informed consent to participate

Exclusion

* Pregnant and/or presenting for antenatal care as reported in records

Exclusion Criteria

* Too ill at the time of study enrollment visit to participate in the study
* Unable to communicate in any of the languages into which the questionnaire has been translated or that is known to the research assistant
* Been on ART \>6 months

Cohort 3

Inclusion

* ≥18 years old
* Living with HIV
* Admitted for inpatient care related to AHD
* Initiated or re-initiated ART within the last 6 months
* Written informed consent to participate

Exclusion

* Pregnant and/or presenting for antenatal care
* Not physically, mentally, or emotionally able to participate in the study prior to discharge, in the opinion of facility or study staff
* Unable to communicate in any of the languages into which the questionnaire has been translated or that is known to the research assistant
* Confined to tuberculosis isolation ward; intensive care unit; or other ward specifically for clients with acute infectious disease.

Cohort 4

Inclusion

* Employed by or at the study site for at least 6 months
* Directly interact with clients presenting with AHD
* Written informed consent to participate

Exclusion

* None

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No